Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
POLIPARIN 25000 IU/5 ml, Heparin sodium, solution for injection and infusion, 25000 IU/5 ml, 5 ml x 1 vial
Non‑compliances were observed involving “nodular clotting after administration of the product in several patients”, with no confirmed cause, which may directly lead to negative health consequences for patients. Potential effects: thrombosis, vascular complications, health risk.
Lipidem
Aggregates were found in the lipid emulsion; intravenous administration of a defective batch without a filter may lead to fat embolism in the capillary vessels of the lungs. Potential effects: pulmonary embolism, respiratory complications, life-threatening condition.
Seronil
It was found that in batches 2127580 and 2132779 the level of the impurity N-nitroso fluoxetine exceeds the temporary limit acceptable to EMA, which means loss of the required quality of the medicine and a potential risk to human health. Potential effects: possible carcinogenic effects with long-term use, impaired treatment efficacy.
Seronil
Exceedance of the temporary limit for the N-nitroso fluoxetine impurity in tablets was found, indicating loss of the required medicinal quality and possible negative impact on efficacy and safety of use. Potential effects: possible toxicity, increased cancer risk, lack of treatment safety.
Fingolimod Stada
Stability studies showed an active substance content lower than required, which, according to the Chief Pharmaceutical Inspector, poses a real risk to patients’ health due to the lack of the intended efficacy of the medicinal product. Potential effects: lack of treatment efficacy and possible worsening of the disease.
Ibuprofen Dr. Max
A justified suspicion of non-compliance with quality requirements concerned the loss on drying parameter for batch DQ2011, which could indicate deviations in capsule quality, but subsequent analyses showed compliance with the extended specification. Potential effects: no significant health effects for patients.
Hydrocortisone (Hydrocortisonum) 100 g/100 g, 1 g pack
In this case it cannot be clearly ruled out that Lidocaine hydrochloride monohydrate raw material was mixed with Hydrocortisone. Consequently, there is a risk of preparing a medicine with a qualitative composition inconsistent with the prescription, which endangers patients’ health and life. Potential effects: lack of treatment efficacy, adverse effects related to the wrong active substance.
Atorvastatin Medical Valley
A quality defect of the tablets was found – surface erosion, defects and uneven coating, which may affect critical quality attributes of the medicine, especially those changing during storage. Potential effects: reduced treatment efficacy or unpredictable drug action.
Hyalgan
The lack of ATD protection on the outer packaging prevents verification of package tampering and full authenticity of the medicine, creating a risk of easy opening of the carton and replacement of the original product with another. Potential effects: medicine falsification, lack of efficacy, complications after injection.
Inuprin Forte
Crystalline sucrose precipitate was observed, which may reduce its concentration in the syrup and the effectiveness of its preservative action, thereby endangering adequate microbiological purity of the medicine, especially during storage after opening. Potential effects: contamination or spoilage of the syrup, possible reduced treatment efficacy.
Bupivacaine WZF Spinal 0,5% Heavy
Insoluble contaminants were detected in some ampoules of the injection solution, which may affect the quality, efficacy and safety of the medicinal product. Potential effects: complications during spinal anaesthesia, inflammatory reactions, lack of efficacy, serious health complications.
Inovox Express Active smak miodowo-cytrynowy
This product does not meet its specified quality requirements due to negative test results for the parameters of alcohol 2,4-dichlorobenzyl content and amylmetacresol content. Potential effects: reduced treatment efficacy or unpredictable drug action.
Lidocaine hydrochloride monohydrate, 100 mg/100 mg, 1 g pack
In one pack of the pharmaceutical raw material Lidocaine hydrochloride monohydrate a different active substance (hydrocortisone) was found, creating a risk of preparing a medicine with a qualitative composition not compliant with the prescription. Potential effects: lack of treatment efficacy, unintended steroid effects, therapy complications.
Seronil
The non-compliance in the level of N-nitroso fluoxetine impurity indicates a loss of the medicine’s quality, and the established acceptance criterion was exceeded, so a risk to human health cannot be excluded. Potential effects: increased risk of toxic effects, complications and altered treatment efficacy.
KIMMTRAK
The identified non‑compliance in the “strength” parameter affects product quality and may impact the effectiveness and safety of its use. A risk to human health cannot be excluded if this batch remains on the market. Potential effects: reduced treatment efficacy or adverse effects.
Magne B6
The failure to meet quality requirements consists in exceeding the lower specification limit for pyridoxine hydrochloride (vitamin B6) release in stability testing under the registered storage conditions. Potential effects: possible reduced treatment effectiveness and lack of the expected supplementation effect.
Elenium
The identified non-compliance in the dissolution rate of the active substance affects the quality of the medicine, which may impact its efficacy and safety; a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, disease worsening, adverse effects related to incorrect dosing.
Elenium
A non-compliance of the active substance dissolution parameter was found in stability studies, meaning reduced and delayed drug release and uncertainty regarding the efficacy and safety of the tablets throughout their shelf life. Potential effects: lack of treatment efficacy, disease complications.
Clatra
Contamination with particles visible to the naked eye was found in Clatra eye drops; the particles correspond to precipitation of the active substance, with a tendency for this phenomenon to increase as the medicine ages. Potential effects: eye irritation, discomfort, possible reduction of treatment efficacy.
Dexapini
Sediment in the form of crystals was found at the bottom of the syrup bottle, not compliant with the quality specification. Failure to determine the cause of crystallization and the risk of disturbed antimicrobial protection and microbiological purity prevent ruling out a risk to patient health. Potential effects: infections, lack of treatment efficacy, health complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.